A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr
A phase 2 trial of Epcoritamab in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.
Overview
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma is a phase 2 interventional study registered as NCT05451810 by Genmab, with 184 participants planned, started 2022-08-17 and due to reach its primary completion in 2027-03. Interventions recorded: Epcoritamab. Conditions listed: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Follicular lymphoma.
- TrialEPCORE DLBCL-2
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Epcoritamab, Genmab, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
- TrialA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Follicular lymphoma.
- CompanyBiogen